Business Wire

Regula Software Now Supports the Latest Standard for Biometric Passport Verification

Share

With its latest update, Regula Document Reader SDK, a comprehensive software solution for identity document verification, ensures 100% support for the new ISO/IEC 39794-5 standard regulating the methods of facial data storage and verification in e-passport chips. According to the ICAO guidelines, all document readers and verification systems must be compatible with the new standard by 2026, with passport issuers required to fully adopt the new format by 2030.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218969889/en/

Regula Document Reader SDK correctly extracts and verifies facial data encoded in the e-passport chip under the new ISO/IEC 39794-5 standard. (Graphic: Regula)

The ISO/IEC 39794-5 standard introduces an enhanced framework for facial image data, significantly improving interoperability, processing speed, and recognition accuracy across different identity verification (IDV) systems worldwide. Unlike the previous ISO/IEC 19794-5:2005 standard, which primarily stored a basic facial image, the new format records additional metadata, including detailed facial landmarks, precise eye and hair color, and other biometric attributes.

Why this matters

The richer set of pre-stored reference points eliminates the need for separate face detection and feature extraction during verification. Instead of calculating key facial points from scratch, IDV systems can use the pre-recorded metadata, accelerating processing times and ensuring consistent, high-quality recognition results—regardless of the local algorithm used for comparison. This standardization guarantees that a person’s face in their passport will be consistently and accurately verified across different countries, improving global interoperability.

Apart from that, the ISO/IEC 39794-5 standard implements a flexible framework for future extensions. This means that as new attributes or enhancements are introduced in the future, all systems supporting this standard will remain fully functional without requiring urgent updates—unlike the current situation, where all IDV systems would need to be updated to accommodate new data formats.

Preparing for the transition

Although the current ISO/IEC 19794-5:2005 will remain valid, the industry has started the transition period, and businesses worldwide should be ready to process the new format data before 2026.

Regula’s long-standing expertise in secure RFID chip reading and trustworthy data verification ensured smooth adaptation to the new standard even prior to its coming into force. The company’s participation in the recent testing event in Australia demonstrated its ability to correctly extract, interpret, and verify biometric facial data encoded according to ISO/IEC 39794-5. This means that identity verification systems using Regula’s software are future-proofed against compatibility issues that could arise as countries transition to the new format.

In addition, the new standard will require organizations from banks to border control to update their passport readers with software that fits this standard. Regula's IDV software is compatible with most document readers on the market and can be easily used with any device model. This implies a seamless transition to the new standard without replacing existing hardware, ensuring a cost-effective and hassle-free upgrade.

“The shift to ISO/IEC 39794-5 is a major step forward in improving compatibility and efficiency in biometric verification. With more detailed metadata now embedded in e-passports, identity verification systems can achieve faster processing and more accurate recognition results. Our expertise in RFID chip processing ensures that Regula’s technology is already fully equipped to support this transition, providing organizations with seamless, future-proof solutions that help them stay in line with regulatory changes,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To get additional information about the latest update to Regula Document Reader SDK, read the technical documentation. If you are interested in learning more about how Regula processes RFID chip data, visit the official website.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250218969889/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye